MET: A narrative review of exon 14 skipping mutation in non-small-cell lung carcinoma

Abstract

The emergence of molecular medicine has led to the increased development and rapid approval of small molecule inhibitors which have caused a dramatic shift in the therapeutic landscape of non-small-cell lung cancer (NSCLC). Mesenchymal epithelial transition factor (MET) exon 14 skipping is one such alteration. This mutation has been reported in 3-4% of NSCLC cases. Additionally, MET exon 14 skipping mutation occurs in 2% of patients with squamous histology NSCLC, and hence, it should be tested in the first line setting. To prepare this review, we searched for articles using the keywords 'MET,' 'exon 14 skipping,' 'capmatinib,' 'tepotinib,' and 'MET TKI' in databases such as PubMed, Scopus, and Embase. There were no defined inclusion/exclusion criteria for our search strategy as this was not a meta-analysis or a systematic review. This narrative review of MET covers its biology, with a special emphasis on exon 14 skipping mutation, its clinical features, and therapeutic options.